Treatment of infections caused by rapidly growing mycobacteria in the era of the newer macrolides

Research in Microbiology

Volumn 147, Issue 1-2, 1996, Pages 30-35

  Wallace Jr , Richard J ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; CEFMETAZOLE; CEFOTAXIME; CEFOXITIN; CEFTRIAXONE; CLARITHROMYCIN; CLAVULANIC ACID; CLOFAZIMINE; DOXYCYCLINE; ETHAMBUTOL; IMIPENEM; KANAMYCIN; MACROLIDE; QUINOLINE; RIFABUTIN; SULFAMETHOXAZOLE; SULFONAMIDE; TETRACYCLINE; TOBRAMYCIN; TRIMETHOPRIM; VANCOMYCIN;

CONFERENCE PAPER; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029982041     PISSN: 09232508     EISSN: None     Source Type: Journal    
DOI: 10.1016/0923-2508(96)80200-2     Document Type: Conference Paper

References (34)

1. Ausina, V., Condom, M.J., Mirelis, B., Luquin, M., Coll, P. & Prats, G. (1986), In vitro activity of clofazimine against rapidly growing nonchromogenic mycobacteria. Antimicrob. Agents Chemother., 29, 951-952.
2. Band, J.D., Ward, J.I., Fraser, D.W., Peterson, N.J., Silcox, V.A., Good, R.C., Ostroy, P.R. & Kennedy, J. (1982), Peritonitis due to a Mycobacterium chelonei-like organism associated with intermittent chronic peritoneal dialysis. J. Infect. Dis., 145, 9-17.
3. Brown, B.A., Wallace, R.J., Jr. Onyi, G.O., De Rosas, V. & Wallace, R.J., III (1992), Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae and M. chelonae-like organisms. Antimicrob. Agents Chemother., 36, 180-184.
4. Casal, M., Rodriguez, F., Benavente, M. & Luna, M. (1986), In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium fortuitum and Mycobacterium chelonei to augmentin. Eur. J. Clin. Microbiol., 5, 453-454.
5. Cynamon, M.H. & Palmer, G.S. (1982), In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins. Antimicrob. Agents Chemother., 22, 1079-1081.
6. Dalovisio, J.R. & Pankey, G.A. (1978), In vitro susceptibility of Mycobacterium chelonei to amikacin. J. Infect. Dis., 137, 318-321.
7. Dalovisio, J.R., Pankey, G.A., Wallace, R.J., Jr. & Jones, D.B. (1981), Clinical usefulness of amikacin and doxycycline in the treatment of infection due to M. fortuitum and M. chelonei. Rev. Infect. Dis., 3, 1068-1074.
8. Franklin, D.J., Starke, J.R., Brady, M.T., Brown, B.A. & Wallace, R.J., Jr. (1994), Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus: A new clinical entity? Am. J. Otol., 15, 313-320.
9. Griffith, D.E., Girard, W.M. & Wallace, R.J., Jr. (1993), Clinical features of pulmonary disease caused by rapidly growing mycobacteria. Am. Rev. Respir. Dis., 147, 1271-1278.
10. Heifets, L.B. & Iseman, M.D. (1985), Determination of in vitro susceptibility of mycobacteria to ansamycin. Am. Rev. Respir. Dis., 132, 710-711.
11. Hoffman, P.C., Fraser, D.W., Robiesek, F., O'Bar, P.R. & Mauney, U. (1981), Two outbreaks of sternal wound infections due to organisms of the Mycobacterium fortuitum complex. J. Infect. Dis., 143, 533-542.
12. Mushatt, D.M. & Witzig, R.S. (1995), Successful treatment of Mycobacterium abscessus infections with multidrug regimens containing clarithromycin. Clin. Infect. Dis., 20, 1441-1442.
13. Newton, J.A., Weiss, P.J., Bowler, W.A. & Oldfield, E.C., III (1993), Soft-tissue infection due to Mycobacterium smegmatis: report of two cases. Clin. Infect. Dis., 16, 531-533.
14. Pang, Y., Brown, B.A., Steingrube, V.A., Wallace, R.J., Jr. & Roberts, M.C. (1994), Tetracycline resistance determinants in Mycobacterium and Streptomyces species. Antimicrob. Agents Chemother., 38, 1408-1412.
15. Rappaport, W., Dunington, G., Norton, L., Ladin, D., Peterson, E. & Ballard, J. (1990), The surgical management of atypical mycobacterial soft-tissue infections. Surgery, 108, 36-39.
16. Silcox, V.A., Good, R.C. & Floyd, M.M. (1981), Identification of clinically significant Mycobacterium fortuitum complex isolates. J. Clin. Microbiol., 14, 686-691.
17. Springer, B., Böttger, E.C., Kirschner, P. & Wallace, R.J., Jr. (1995), Phylogeny of the Mycobacterium chelonae-like organism based on partial sequencing of the 16S rRNA gene and proposal of Mycobacterium mucogenicum sp. nov. Int. J. Syst. Bacteriol., 45, 262-267.
18. Swenson, J.M., Thornsberry, C. & Silcox, V.A. (1982), Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents of broth microdilution. Antimicrob. Agents Chemother., 22, 186-192.
19. Swenson, J.M., Wallace, R.J., Jr., Silcox, V.A. & Thornsberry, C. (1985), Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob. Agents Chemother., 28, 807-811.
20. Tebas, P., Sultan, F., Wallace, R.J., Jr. & Fraser, V. (1995), Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in heart transplant patient. Clin. Infect. Dis., 20, 443-444.
21. Tsui, S.Y.T., Yew, W.W., Li, M.S.K., Chan, C.Y. & Cheng, F.B. (1993), Postantibiotic effects of amikacin and ofloxacin on Mycobacterium fortuitum. Antimicrob. Agents Chemother., 37, 1001-1003.
22. Wallace, R.J., Jr., Hull, S.I., Bobey, D.G., Price, K.E., Swenson, J.M., Steele, L.C. & Christensen, L. (1985), Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Am. Rev. Respir. Dis., 132, 409-416.
23. Wallace, R.J., Jr., Bedsole, G., Sumter, G., Sanders, C.V., Steele, L.C., Brown, B.A., Smith, J. & Graham, D.R. (1990), Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob. Agents Chemother., 34, 65-70.
24. Wallace, R.J., Jr., Brown, B.A. & Onyi, G.O. (1991a), Susceptibilities of Mycobacterium fortuitum biovar fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob. Agents Chemother., 35, 773-775.
25. Wallace, R.J., Jr., Brown, B.A., Silcox, V.A., Tsukamura, M., Nash, D.R., Steele, L.C., Steingrube, V.A., Smith, J., Sumter, G., Zhang, Y. & Blacklock, Z. (1991b), Clinical disease, drug susceptibility, and biochemical patterns of the unnamed third biovariant complex of Mycobacterium fortuitum. J. Infect. Dis., 163, 598-603.
26. Wallace, R.J., Jr., Brown, B.A. & Onyi, G.O. (1992), Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J. INfect. Dis., 166, 405-412.
27. Wallace, R.J., Jr., Jones, D.B., & Wiss, K. (1981), Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei. Rev. Infect. Dis., 3, 898-904.
28. Wallace, R.J., Jr., Swenson, J.M., Silcox, V.A., Good, R.C., Tschen, J.A. & Stone, M.S. (1983), Spectrum of disease due to rapidly growing mycobacteria. Rev. Infect. Dis., 5, 657-679.
29. Wallace, R.J., Jr., Swenson, J.M., Silcox, V.A. & Bullen, M.G. (1985), Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J. Infect. Dis., 152, 500-514.
30. Wallace, R.J., Nash, D.R., Tsukamura, M., Blacklock, Z.M. & Silcox, V.A. (1988), Human disease due to Mycobacterium smegmatis. J. Infect. Dis., 158, 52-59.
31. Wallace, R.J., Jr., Silcox, V.A., Tsukamura, M., Brown, B.A., Kilburn, J.O., Butler, W.R. & Onyi, G.O. (1993a), Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism. J. Clin. Microbiol., 31, 3231-3239.
32. Wallace, R.J., Jr., Tanner, D., Brennan, P.J. & Brown, B.A. (1993b), Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann. Intern. Med., 119, 482-486.
33. Welch, D.F. & Kelly, M.T. (1979), Antimicrobial susceptibility testing of Mycobacterium fortuitum complex. Antimicrob. Agents Chemother., 15, 754-757.
34. Zahid, M.A., Klotz, S.A., Goldstein, E. & Bartholomew, W. (1994), Mycobacterium chelonae (M. chelonae subspecies chelonae): report of a patient with a sporotrichoid presentation who was successfully treated with clarithromycin and ciprofloxacin. Clin. Infect. Dis., 18, 999-1001.